Identification | Back Directory | [Name]
GC376 | [CAS]
1416992-39-6 | [Synonyms]
376 GC376 GPC376 GC376 sodium 3 alpha, 7 alpha-dyhydroxy-6-ethidene- cholanic acid Sodium (2S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanamido)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate | [Molecular Formula]
C21H32N3NaO8S | [MDL Number]
MFCD31382192 | [MOL File]
1416992-39-6.mol | [Molecular Weight]
509.55 |
Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMF: 10 mg/ml,DMSO: 10 mg/ml,PBS (pH 7.2): 10 mg/ml | [form ]
A crystalline solid | [color ]
Off-white to yellow | [InChIKey]
FEDHEMZBPAZOSQ-IUZIYNMENA-N | [SMILES]
[C@]([H])(C(O)S(O)(=O)=O)(NC(=O)[C@H](CC(C)C)NC(=O)OCC1C=CC=CC=1)CC1CCNC1=O.[NaH] |&1:0,11,r| |
Hazard Information | Back Directory | [Description]
GC376 is an inhibitor of the main protease Mpro (3CLpro) in coronaviruses as well as picornaviruses. This broad-spectrum antiviral compound has been used as investigational veterinary drug for treatment of feline infectious peritonitis virus (FIPV) infections. Recent studies also showed that GC376 inhibits the main protease Mpro (3CLpro) from SARS-CoV-2 with IC50 of 0.03 μM and EC50 of 3.37 μM. | [Uses]
GC 376 sodium is a potential small molecule inhibitor which may be able to reduce the viral load of SARS-CoV-2 3CLpro. | [in vivo]
GC376 sodium exhibits favorable bioavailability and safety in cats. GC376 sodium is rapidly absorbed after s.c. administration and the peak plasma level is reached within 2 hr after injection. The mean plasma drug concentrations remains above the 50% effective concentration (EC50) value of the aldehyde form of GC376 (8 ng/mL) for 18 hrs post injection. Virus infected cats shows improvement in attitude and resolution of fever. The profound absolute lymphopenia observed in all cats prior to antiviral treatment also returns to normal before the next blood testing one week later[3]. Nineteen of 20 cats treated with GC376 sodium regain outward health within 2 weeks of initial treatment. However, disease signs recur 1-7 weeks after primary treatment and relapses and new cases are ultimately treated for a minimum of 12 weeks[4]. |
|
|